We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Johnson & Johnson, Planning for Future Pandemics, Invests Up to $780 Million in Flu Drugs
Johnson & Johnson, Planning for Future Pandemics, Invests Up to $780 Million in Flu Drugs
Johnson & Johnson subsidiary Janssen has agreed to pay up to $780 million for the global rights to Cidara Therapeutics’ Cloudbreak antiviral conjugate (AVC) candidates being developed for preventing and treating seasonal and pandemic influenza.